Literature DB >> 11751631

Induction and apoptotic regression of lung adenocarcinomas by regulation of a K-Ras transgene in the presence and absence of tumor suppressor genes.

G H Fisher1, S L Wellen, D Klimstra, J M Lenczowski, J W Tichelaar, M J Lizak, J A Whitsett, A Koretsky, H E Varmus.   

Abstract

To investigate the role of an activated K-Ras gene in the initiation and maintenance of lung adenocarcinomas, we developed transgenic mice that express murine K-Ras4b(G12D) under the control of doxycycline in type II pneumocytes. Focal proliferative lesions of alveolar type II pneumocytes were observed as early as seven days after induction with doxycycline; after two months of induction, the lungs contained adenomas and adenocarcinomas, with focal invasion of the pleura at later stages. Removal of doxycycline caused a rapid fall in levels of mutant K-Ras RNA and concomitant apoptotic regression of both the early proliferative lesions and the tumors. Tumor burden was dramatically decreased by three days after withdrawal, and tumors were undetectable after one month. When similar experiments were performed with animals deficient in either the p53 gene or the Ink4A/Arf locus, tumors arose more quickly (within one month of exposure to doxycycline) and displayed more obvious histological features of malignancy; nevertheless, these tumors also regressed rapidly when the inducer was removed, implying that continued production of mutant K-Ras is necessary to maintain the viability of tumor cells in the absence as well as the presence of tumor suppressor genes. We also show that the appearance and regression of these pulmonary tumors can be readily monitored in anesthetized transgenic animals by magnetic resonance imaging.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11751631      PMCID: PMC312852          DOI: 10.1101/gad.947701

Source DB:  PubMed          Journal:  Genes Dev        ISSN: 0890-9369            Impact factor:   11.361


  44 in total

Review 1.  Activation of p53 by oncogenes.

Authors:  S W Lowe
Journal:  Endocr Relat Cancer       Date:  1999-03       Impact factor: 5.678

Review 2.  The ARF/p53 pathway.

Authors:  C J Sherr; J D Weber
Journal:  Curr Opin Genet Dev       Date:  2000-02       Impact factor: 5.578

Review 3.  p53: death star.

Authors:  K H Vousden
Journal:  Cell       Date:  2000-11-22       Impact factor: 41.582

Review 4.  Applications of magnetic resonance in model systems: cancer therapeutics.

Authors:  J L Evelhoch; R J Gillies; G S Karczmar; J A Koutcher; R J Maxwell; O Nalcioglu; N Raghunand; S M Ronen; B D Ross; H M Swartz
Journal:  Neoplasia       Date:  2000 Jan-Apr       Impact factor: 5.715

Review 5.  Molecular pathogenesis of lung cancer.

Authors:  K M Fong; Y Sekido; J D Minna
Journal:  J Thorac Cardiovasc Surg       Date:  1999-12       Impact factor: 5.209

6.  FGF-10 disrupts lung morphogenesis and causes pulmonary adenomas in vivo.

Authors:  J C Clark; J W Tichelaar; S E Wert; N Itoh; A K Perl; M T Stahlman; J A Whitsett
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2001-04       Impact factor: 5.464

7.  Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a.

Authors:  M Serrano; A W Lin; M E McCurrach; D Beach; S W Lowe
Journal:  Cell       Date:  1997-03-07       Impact factor: 41.582

8.  Basic fibroblast growth factor induces cell migration and proliferation after glia-specific gene transfer in mice.

Authors:  E C Holland; H E Varmus
Journal:  Proc Natl Acad Sci U S A       Date:  1998-02-03       Impact factor: 11.205

Review 9.  Molecular abnormalities in lung cancer.

Authors:  R Salgia; A T Skarin
Journal:  J Clin Oncol       Date:  1998-03       Impact factor: 44.544

10.  Conditional expression of fibroblast growth factor-7 in the developing and mature lung.

Authors:  J W Tichelaar; W Lu; J A Whitsett
Journal:  J Biol Chem       Date:  2000-04-21       Impact factor: 5.157

View more
  247 in total

Review 1.  Genetically Engineered Mouse Models of K-Ras-Driven Lung and Pancreatic Tumors: Validation of Therapeutic Targets.

Authors:  Matthias Drosten; Carmen Guerra; Mariano Barbacid
Journal:  Cold Spring Harb Perspect Med       Date:  2018-05-01       Impact factor: 6.915

2.  A new start in Madrid. Symposium on basic and translational cancer research.

Authors:  Julio E Celis
Journal:  EMBO Rep       Date:  2002-08       Impact factor: 8.807

Review 3.  Pro-oncogenic and anti-oncogenic pathways: opportunities and challenges of cancer therapy.

Authors:  Jiao Zhang; Yan-Hua Chen; Qun Lu
Journal:  Future Oncol       Date:  2010-04       Impact factor: 3.404

Review 4.  The impact of the Cancer Genome Atlas on lung cancer.

Authors:  Jeremy T-H Chang; Yee Ming Lee; R Stephanie Huang
Journal:  Transl Res       Date:  2015-08-10       Impact factor: 7.012

Review 5.  KRAS as a Therapeutic Target.

Authors:  Frank McCormick
Journal:  Clin Cancer Res       Date:  2015-04-15       Impact factor: 12.531

Review 6.  Developing better mouse models to study cisplatin-induced kidney injury.

Authors:  Cierra N Sharp; Leah J Siskind
Journal:  Am J Physiol Renal Physiol       Date:  2017-07-19

7.  Wild-type H- and N-Ras promote mutant K-Ras-driven tumorigenesis by modulating the DNA damage response.

Authors:  Elda Grabocka; Yuliya Pylayeva-Gupta; Mathew J K Jones; Veronica Lubkov; Eyoel Yemanaberhan; Laura Taylor; Hao Hsuan Jeng; Dafna Bar-Sagi
Journal:  Cancer Cell       Date:  2014-02-10       Impact factor: 31.743

8.  Erlotinib resistance in mouse models of epidermal growth factor receptor-induced lung adenocarcinoma.

Authors:  Katerina Politi; Pang-Dian Fan; Ronglai Shen; Maureen Zakowski; Harold Varmus
Journal:  Dis Model Mech       Date:  2009-12-09       Impact factor: 5.758

9.  Usefulness of peptide nucleic acid (PNA)-clamp smart amplification process version 2 (SmartAmp2) for clinical diagnosis of KRAS codon 12 mutations in lung adenocarcinoma: comparison of PNA-clamp SmartAmp2 and PCR-related methods.

Authors:  Takuya Araki; Kimihiro Shimizu; Katsunori Nakamura; Tomonori Nakamura; Yasumasa Mitani; Kyoko Obayashi; Yukiyoshi Fujita; Seiichi Kakegawa; Yohei Miyamae; Kyoichi Kaira; Takefumi Ishidao; Alexander Lezhava; Yoshihide Hayashizaki; Izumi Takeyoshi; Koujirou Yamamoto
Journal:  J Mol Diagn       Date:  2009-12-10       Impact factor: 5.568

10.  Protein kinase Czeta represses the interleukin-6 promoter and impairs tumorigenesis in vivo.

Authors:  Anita S Galvez; Angeles Duran; Juan F Linares; Peterson Pathrose; Elias A Castilla; Shadi Abu-Baker; Michael Leitges; Maria T Diaz-Meco; Jorge Moscat
Journal:  Mol Cell Biol       Date:  2008-10-27       Impact factor: 4.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.